



REVIEW

Prevalence and Risk Factors of Human Leishmaniasis in Ethiopia: A Systematic Review and Meta-Analysis

Mekonnen Haftom · Pammla Petrucka · Kbrom Gemechu ·
Jemila Nesro · Embay Amare · Tsegu Hailu · Yohannes Ashebir ·
Gdiom Gebreheat · Haftea Hagos · Destaalem Gebremedhin ·
Alem Gebremariam

Received: September 7, 2020 / Accepted: October 15, 2020 / Published online: November 10, 2020
© The Author(s) 2020

ABSTRACT

Introduction: Tropical diseases are public health problems affecting hundreds of millions of people globally. However, the development of adequate, affordable, and accessible treatments is mostly neglected, resulting in significant morbidity and mortality that could otherwise be averted. Leishmaniasis is one of the neglected tropical diseases caused by the obligate intracellular protozoan *Leishmania* parasite and transmitted by the bite of infected phlebotomine sandflies. No systematic review and meta-analysis has been done to identify the prevalence and risk factors of leishmaniasis to the authors' knowledge. Therefore, the

objective was to determine the prevalence and risk factors of human leishmaniasis in Ethiopia.

Methods: Eleven studies conducted in all regions of Ethiopia, which were fully accessible, written in any language, and original articles done on prevalence and risk factors of leishmaniasis, were included. STATA™ version 11.1 was used for statistical analysis. Chi-square, I^2 , and p values were assessed to check heterogeneity. A random effects model with heterogeneity taken from an inverse-variance model was employed to estimate the pooled effect. Subgroup meta-analysis was computed to reduce random variations among each article's point prevalence, and Egger and funnel plots were used to check for publication bias.

Results: The highest proportion of human leishmaniasis was reported from a study done in Amhara region (39.1%), and the lowest was reported from a survey done in Tigray (2.3%). The overall pooled prevalence of leishmaniasis was 9.13% (95% CI 5–13.27). Subgroup analysis by region revealed moderate heterogeneity ($I^2 = 51.8%$) in studies conducted in the Southern Nations Nationalities and Peoples Region (SNNPR). The presence of hyraxes and being male were associated with an increased risk of human leishmaniasis.

Conclusion: The prevalence of leishmaniasis in Ethiopia remains high (9.13%), with significant risk factors being male and the presence of hyraxes within a 300-m radius of the sleeping area.

M. Haftom (✉) · K. Gemechu · T. Hailu · Y. Ashebir
· G. Gebreheat · H. Hagos · D. Gebremedhin
Department of Nursing, College of Medicine and
Health Sciences, Adigrat University, Adigrat,
Ethiopia
e-mail: haftommekonnen@gmail.com

P. Petrucka
College of Nursing, University of Saskatchewan,
Saskatchewan, Canada

J. Nesro
Department of Midwifery, College of Medicine and
Health Science, Jima University, Jima, Ethiopia

E. Amare · A. Gebremariam
Department of Public Health, College of Health
Sciences, Adigrat University, Adigrat, Ethiopia

Keywords: Ethiopia; Infectious disease; Leishmaniasis; Neglected tropical diseases; Prevalence

Key Summary Points

Globally, neglected tropical diseases affect hundreds of millions and place even more at risk, and nearly 40 million people are suffering from stigma secondary to one such disease, cutaneous leishmaniasis.

World Health Organization/Tropical Disease Research program focuses on the development of new diagnostics, vaccines, and drugs to combat these complex conditions. However, tropical diseases are globally dispersed, making it difficult for the treatment to be available and affordable for those most in need, who are often socioeconomically and politically marginalized (like Ethiopia).

Leishmaniasis impacts public health, socioeconomics, and the nation's economy and growth. There is lack of systematic review and meta-analysis on prevalence and risk factors of human leishmaniasis at country level. This direction further indicated a need to assess the prevalence and risk factors of human leishmaniasis.

Such a gap in knowledge further complicates the full understanding and evidentiary base needed to combat this disease. Therefore, this study determined the pooled prevalence and risk factors of human leishmaniasis in Ethiopia.

The prevalence of leishmaniasis remains high in Ethiopia (9.13%), and gender (male) and the presence of hyraxes within a 300-m radius of the sleeping area were significant risk factors. Vaccine development, methods of diagnosis, and treatment that can be affordable for developing countries should be given priority.

DIGITAL FEATURES

This article is published with digital features, including a summary slide, to facilitate understanding of the article. To view digital features for this article go to <https://doi.org/10.6084/m9.figshare.13055780>

INTRODUCTION

Globally, an estimated of 58,000 new cases of visceral leishmaniasis and 220,000 new cases of cutaneous leishmaniasis occur every year [1]. Nearly 40 million people are suffering from stigma due to inactive cutaneous leishmaniasis scars [2]. Neglected tropical diseases are a significant public health problem in Ethiopia, which is experiencing a considerable burden compared to other sub-Saharan African countries [3]. Leishmaniasis affects both humans and animals [4, 5]. The prevalence of animal leishmaniasis in Ethiopia was 11% (95% CI 5–16%) [6]. Neglected tropical diseases resulted in 3593 deaths in 2015 in Ethiopia [7]. Within Ethiopia, there are many neglected tropical diseases that result in the loss of quality of life and loss of lives. One such disease, leishmaniasis, a protozoan disease, is caused by over 20 different *Leishmania* spp., which are transmitted by female phlebotomine sandflies to humans [8]. The presentation of leishmaniasis can be sub-clinical, localized, or disseminated with its symptomatic stage manifesting as either acute or chronic [9]. There are three major types of the disease: visceral, cutaneous, and mucocutaneous [10], with consequences ranging from skin lesions to death [11]. East Africa is the second-largest visceral leishmaniasis focus after the Indian subcontinent. East Africa contributes 30,000–40,000 new cases per year to the global burden, with the largest proportion of new leishmaniasis cases occurring in Ethiopia, South Sudan, and Sudan [12, 13]. Visceral leishmaniasis is characterized by anemia, prolonged fever, weight loss, and hepatosplenomegaly. If left untreated, it is fatal in 95% of cases [14, 15].

Globally, tropical diseases affect hundreds of millions and place even more at risk [8, 16]. The World Health Organization/Tropical Disease

Research (WHO/TDR) program focuses on the development of new diagnostics, vaccines, and drugs to combat these complex conditions. However, tropical diseases are globally dispersed, making it difficult for the treatment to be available and affordable for those most in need, who are often socioeconomically and politically marginalized. Furthermore, drug development is mostly neglected because of the relatively small populations affected, coupled with users' inability to pay for such drugs [16, 17].

Leishmaniasis impacts public health, socioeconomics, and the nation's economy and growth [18]. Leishmaniasis causes high mortality, morbidity, affects the quality of life, causes mental illness, stigma, and psychosocial morbidity among those affected [17, 19]. Assefa did a systematic review and meta-analysis on leishmaniasis [6]. But it was focused on the prevalence of leishmaniasis among humans and animals. This direction further indicated a need to assess the prevalence and risk factors of human leishmaniasis as there is a lack of systematic review and meta-analysis on prevalence and risk factors of human leishmaniasis at the country level [1]. Such a gap in knowledge further complicates the full understanding and evidentiary base needed to combat this disease. Therefore, this study determined the pooled prevalence and risk factors of human leishmaniasis in Ethiopia.

METHODS

Study Area and Design

This systematic review and meta-analysis considered original studies, including cross-sectional and retrospective cohort studies, conducted in all Ethiopian regions on prevalence and factors associated with leishmaniasis. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Eligibility Criteria and Search Strategy

Inclusion Criteria

Fully accessible (either through online, library, or author access at no cost) published articles concerned with leishmaniasis prevalence and risk factors, peer-reviewed, published in any language, and including Ethiopian populations.

Exclusion Criteria

We excluded systematic reviews, meta-analysis, commentaries, case-control (denominators are already predetermined), case series, case reports, studies done in animals, and inaccessible articles (unable to contact the primary author after three attempts to retrieve the full text of the papers). Following the Preferred Reporting Item for Systematic Review and Meta-analysis (PRISMA) guidelines [20], a comprehensive computer search in PubMed, Google Scholar, Cochrane Library, Science Direct, African Journals Online, and JURN on prevalence and risk factors of leishmaniasis was performed. The search was done with geographical location restricted to Ethiopia. Related articles and references were identified from some included articles and were also searched. Boolean operators ("OR" or "AND") were used in combination or separately to search the terms. Peer-reviewed articles published from November 1993 until December 2019, which were fully accessible, were included. Medical Subject Headings (MeSH) terms (((magnitude) OR leishmaniasis) OR associated factors) OR Ethiopia, (((prevalence) OR leishmaniasis) OR risk factors) OR Ethiopia) were initially used. The last search was done using (((prevalence) AND leishmaniasis) AND risk factors) AND Ethiopia.

Study Selection and Quality Assessment

Three individuals (MH, KG, and JN) searched the electronic databases using similar MeSH terms to identify possible eligible articles on the basis of the title and abstracts imported to Endnote version 7 (Thomson Reuters, NY, USA). Duplicate reports were removed. Title and abstract reviews were performed. Articles with adequate data concerning the inclusion criteria




Fig. 1 PRISMA flowchart showing the number of articles identified in the systematic review and meta-analysis on the prevalence of human leishmaniasis and associated factors

were saved for full-text assessment. The Newcastle–Ottawa Scale [21] adapted for cross-sectional study quality assessment was used to assess the quality of each article. Each article was scored by three reviewers independently. In the event of disagreements, the reviewers reached a consensus or voted to determine the disposition of the article. Articles with a quality assessment score of greater than 6/10 were considered high quality and were included in this review.

Data Extraction

Three individual reviewers (MH, KG, and JN) independently conducted the data extraction using a standardized data extraction checklist. The checklist included the name of the first author, prevalence, standard error, type of

test, year of publication, a region of the study, study setting, study population, gender of participants, age, study design, sample size, type of leishmaniasis, and other variables. If authors disagreed on whether to include or exclude an article, a majority decision was made (Fig. 1).

Data Analysis

STATATM version 11.1 statistical software was used for analysis. The standard error for each original study was calculated using the binomial distribution formula. Chi-square, I^2 , and p values were assessed to check heterogeneity. Though the pooled I^2 shows no heterogeneity, we queried differences in assumptions amongst the individual studies. Therefore, a random effects model with heterogeneity

Table 1 Descriptive summary of the 11 studies done on prevalence and risk factors of human leishmaniasis in Ethiopia

Authors	Year of publication	Sample size	Type of test	Region of the study	Study setting	Prevalence (95% CI)
Ali et al.	1993	730	rK39	SNNPR	Community	36.4 (10.91–61.89)
Negera et al.	2008	1907	rK39	SNNPR	Community	4.8 (– 13.54 to 23.14)
Wondimeneh et al.	2014	7161	DAT	Amhara	Hospital	39.1 (– 41.84 to 120.04)
Bsrat et al.	2015	2106	rK39	Tigray	Community	14.0 (– 17.22 to 45.22)
Abera et al.	2016	289	rK39	Somali or Benshangul	Community	6.9 (– 1.56 to 15.36)
Bsrat et al.	2018	329	rK39	Tigray	Community	8.8 (– 1.28 to 18.88)
Tedla et al.	2018	26,511	rK39	Tigray	Hospital	8.4 (– 80.21 to 97.01)
Ayehu et al.	2018	185	rK39	Amhara	Community	7.6 (0.55–14.65)
Bekele et al.	2018	1682	rK39	SNNPR	Community	8.6 (– 13.96 to 31.16)
Alebie et al.	2019	361	rK39	Somali or Benshangul	Community	15.8 (2.22–29.38)
Yohannes et al.	2019	9622	Clinical	Tigray	Community	2.3 (– 26.50 to 31.10)

taken from an inverse-variance model (DerSimonian and Laird, 1986) was employed to estimate the pooled effect. Subgroup meta-analysis was computed on the basis of the type of study design, the region where the research was conducted, and the type of leishmaniasis to reduce random variations among the point prevalence of each article. Egger and funnel plot tests were done to check for publication bias. First author, year of publication, point prevalence, and 95% confidence interval were presented using forest plots. Each identified potential determinant factor was checked regarding the effect on the prevalence of human leishmaniasis. The size of each box on the forest plot indicates the weight of each article, and the cross lines refer to a 95% confidence interval.

RESULTS

Descriptive and Meta-Analysis

The years of publication of included articles ranged from November 1993 to September 2019. Of the total articles that fulfilled the eligibility criteria, 11 were selected for systematic review and meta-analysis, ten of which were community-based. The total sample size included from all the eligible articles was 50,883. Over one-third (36.36%) of the studies were conducted in the Tigray region. The highest proportion of leishmaniasis was reported from a study done in Amhara region (39.1%), followed by SNNPR (36.4%), and the lowest prevalence was reported from a study done in Tigray region (2.3%) [22–24] (Table 1). Of the 11 studies, nine




Fig. 2 Forest plot of pooled prevalence of human leishmaniasis in Ethiopia

studies were cross-sectional [22, 24–31], and the rest [23, 32] were retrospective studies. Included studies were done in five of the nine regions of the country. Although the value of $I^2 = 0.0\%$, differences in the assumptions of individual articles were expected; hence, a random effects model was employed using sample size and positive participants to determine the country-level pooled prevalence. The overall pooled prevalence of leishmaniasis was 9.13% (95% CI 5–13.27) with heterogeneity chi-squared = 6.83, $p = 0.741$, $df = 10$, and $I^2 = 0.0\%$ (Fig. 2).

Subgroup Meta-Analysis

Subgroup meta-analysis was done on the basis of the region of the study, the type of leishmaniasis, and type of study design employed. Subgroup analysis by region (SNNPR, Tigray, Amhara, Somali, and Benshangul Gumuz) revealed moderate heterogeneity ($I^2 = 51.8\%$) in

studies conducted in SNNPR. No heterogeneity was observed regarding study designs, and subtotal random proportion of the study designs showed that 9.13% (95% CI 4.91–13.21) was attributable to cross-sectional study design (Table 2). Regarding the type of leishmaniasis, the pooling subtotal under a random effects model implies that 9.44% (95% CI 5.1–13.78) of the type of leishmaniasis was visceral (kala-azar), and the subtotal prevalence for cutaneous leishmaniasis was 6.03% (95% CI 7.83–19.9) (Fig. 3).

Factors Associated with Human Leishmaniasis

A total of 23 variables (Table 3) were examined in this review for their effect on human leishmaniasis prevalence. Thirteen of the variables (i.e., the residence of daily laborers, knowledge about the mode of transmission, dog

Table 2 Prevalence of human leishmaniasis estimates by subgroup analysis in the region and study design

Region/study design	Authors	RR	95% CI	Weight	Heterogeneity statistic	df	<i>p</i> value	<i>I</i> -squared	Tau-squared						
SNNPR	Ali et al. (1993)	36.4	10.9–61.9	2.6	4.2	3	0.13	51.8%	134.7						
	Negera et al. (2008)	4.8	– 13.5 to 23.1	5.1											
	Bekele et al. (2018)	8.6	– 14 to 31.2	3.4											
	Pooled effect size	15.1	– 3.2 to 33.3	11.1											
Tigray	Bsrat et al. (2015)	14	– 17.2 to 45.2	1.8	0.3	3	0.96	0.0%	0.00						
	Bsrat et al. (2018)	8.8	– 1.3 to 18.9	16.9											
	Tedla et al. (2018)	8.4	– 80.2 to 97	0.2											
	Yohannes et al. (2019)	2.3	– 26.5 to 31.1	2.1											
	Pooled effect size	8.6	– 0.5 to 17.6	20.9											
Amhara	Wondimeneh et al. (2018)	39.1	– 41.8 to 120	0.3	0.6	1	0.45	0.0%	0.00						
	Ayehu et al. (2018)	7.6	0.5–14.7	34.6											
	Pooled effect size	7.8	0.8–14.9	34.7											
Somali or Benshangul Gumuz	Abera et al. (2016)	6.9	– 1.6 to 15.4	24	1.2	1	0.28	15.9%	6.30						
	Alebie et al. (2019)	15.8	2.2–29.4	9.3											
	Pooled effect size	9.7	1.6–17.8	33.3											
	Overall pooled effect	9.13	5–13.3	100											
Cross-sectional	Ali et al. (1993)	36.4	10.9–61.9	2.6	6.3	8	0.6	0.0%	0.00						
	Negera et al. (2008)	4.8	– 13.5 to 23.1	5.1											
	Bsrat et al. (2015)	14	– 17.2 to 45.2	1.8											
	Abera et al. (2016)	6.9	– 1.6 to 15.4	24											
	Bekele et al. (2018)	8.6	– 14 to 31.2	3.4											
	Bsrat et al. (2018)	8.8	– 1.3 to 18.9	16.9											
	Ayehu et al. (2018)	7.6	0.5–14.7	34.6											
	Alebie et al. (2019)	15.8	2.2–29.4	9.3											
	Yohannes et al. (2019)	2.3	– 26.5 to 31.1	16.9											
	Pooled effect size	9.1	4.9–13.2	99.5											
	Retrospective cross-sectional	Wondimeneh et al. (2018)	39.1	– 41.8 to 120						0.3	0.25	1	0.6	0.0%	0.00
		Tedla et al. (2018)	8.4	– 80.2 to 97						0.2					
		Pooled effect size	25.1	– 34.6 to 85						0.5					
		Overall pooled effect	9.13	5–13.3						100					




Fig. 3 Subgroup meta-analysis by type of human leishmaniasis in Ethiopia

ownership, educational status, presence of termite mounds, presence of bed nets, resettlement status, the residence of participants, sleeping under a Ballantine tree, type of house, season, origin, and presence of cave within a 300-m radius) were mentioned in single articles as risk factors. Therefore, the pooled effect was not calculated for such variables. From the remaining ten variables tested for their effect on the prevalence of human leishmaniasis, the presence of hyraxes within a 300-m radius of sleep area and gender were significantly associated with the prevalence of human leishmaniasis in the final systematic review and meta-analysis. Pooling from two studies [24, 30] showed that the presence of hyraxes within a 300-m radius of the sleeping area was associated

with the prevalence of human leishmaniasis (OR 2.96; 95% CI 1.67–5.245). Pooling from ten studies [22–30, 32] showed that female individuals were less likely to be affected by leishmaniasis compared to their male counterparts (OR 0.6; 95% CI 0.46–0.82). No other study variables showed an association with the prevalence of human leishmaniasis (Table 4).

Publication Bias and Small Study Effect Assessment

Egger and funnel plot tests were done to determine publication bias (Fig. 4), yielding no evidence of bias with a p value of 0.19 (95% CI – 0.356 to 1.548).

Table 3 Select risk factors for human leishmaniasis in Ethiopia

Sociodemographic	Residence/ accommodation	Sleeping related	Environmental	Health behaviors
Sex	Residence of daily laborers	Indoor/outdoor	Acacia	Bed Nets
Age	House materials (mud, stone, wood/mud)	Domestic animals sleeping nearby	Termite mounds	Knowledge of transmission modes
Origin (high/lowland)	Resettlement status	Sleeping under Ballantine tree	Dog ownership	Travel history to endemic areas
Occupation (farmer/not farmer)		Cave within 300-m radius	Black and cracked soil	
Residence (rural/urban)		Gorge within 300-m radius	Season (dry/wet)	
Education (formal/no formal)		Hyraxes within 300-m radius		

DISCUSSION

Despite the prevalence of neglected tropical diseases in Ethiopia, funding to control and investigate geographic distribution is limited [3]. Risk assessment at the country level is poor in Ethiopia and the non-specific symptoms of leishmaniasis have made it difficult to treat. Many of the available methods of diagnosis are not appropriate in Ethiopia [10]. Therefore, this study focused on prevalence and risk factors of human leishmaniasis at the country level.

Human leishmaniasis was present, highly prevalent, and reported in more than half of the regions of the country. These findings are supported by previous studies suggesting that the Horn of Africa bears the largest burden of leishmaniasis with northern regions of Ethiopia around the borders of Sudan most affected [33, 34]. This pattern might reflect the unavailability of a vaccine, inadequate vector control, and insufficient access to new drugs [9]. Others suggest that this trend might be due to migration and conflict [34]; lack of advancement in diagnostics and treatment of the disease; or unaffordability of the new advanced technologies (i.e., vaccine, treatment, and diagnostics) to eradicate leishmaniasis [35].

Leishmaniasis was more prevalent in Amhara region followed by SNNPR, showing low reported prevalence in Tigray. Visceral leishmaniasis was the most prevalent type across all regions. This study showed that the risk of having leishmaniasis is increased among male individuals, which mirrors a previous study in Sudan [36]. This finding could potentially reflect that male individuals are more likely to be in agricultural fields and move during the night. This study showed that the presence of hyraxes within a 300-m radius of the sleeping area increased the risk of acquiring the disease. Previous studies revealed similar findings [12, 37] with an explanation that hyraxes are natural reservoirs of leishmaniasis [3]. In some studies, the presence of domestic animals around sleeping areas was ambiguous for risk factors for the prevalence of leishmaniasis [36, 38], although this finding was less evident in another study [37].

In contrast, the current study revealed that the presence of domestic animals does not affect the prevalence of leishmaniasis. This systematic review and meta-analysis showed that the remaining variables (Table 4) did not affect leishmaniasis prevalence. These findings are in disagreement with previous studies that suggest

Table 4 Effect of selected risk factors for human leishmaniasis in Ethiopia

Variables	Authors	RR	95% CI	% Weight	Heterogeneity chi-squared	df	<i>p</i> value	<i>I</i> -squared	Tau-squared					
Gender	Ali et al. (1993)	0.9	0.8–1.1	17.4	70.0	9	0.00	7.1%	0.12					
	Wondimeneh et al. (2014)	0.9	0.9–0.98	18										
	Bsrat et al. (2015)	0.8	0.6–1.1	14.9										
	Abera et al. (2016)	0.2	0.06–0.4	4.3										
	Bekele et al. (2018)	0.2	0.1–0.4	7.9										
	Bsrat et al. (2018)	0.1	0.0–0.3	3.4										
	Tedla et al. (2018)	0.0	0.01–0.1	4.7										
	Ayehu et al. (2018)	2.2	0.2–29.4	1.2										
	Alebie et al. (2019)	1.2	0.8–2	12										
	Yohannes et al. (2019)	0.0	0.7–1.1	15.8										
	Pooled RR	0.6	0.5–0.8	100										
Presence of hyraxes	Bsrat et al. (2015)	2.3	1.7–3	54.6	4.8	1	0.03	79%	0.13					
	Yohannes et al. (2019)	4.1	2.6–6.4	45.4										
	Pooled RR	3	1.7–5.2	100										
Age	Ali et al. (1993)	0.5	0.4–0.6	15	114.6	7	0.00	93.9%	0.38					
	Negera et al. (2008)	1.5	0.9–2.5	13										
	Wondimeneh et al. (2014)	1.5	1.4–1.6	15.5										
	Abera et al. (2016)	0.7	0.3–1.8	10										
	Bsrat et al. (2018)	2	1–4.1	11.4										
	Bekele et al. (2018)	2.9	0.9–9.5	8										
	Alebie et al. (2019)	1.5	0.9–2.6	12.8										
	Yohannes et al. (2019)	2.9	2–4.3	14.2										
		Pooled RR	1.4	0.9–2.3						100				
	Sleeping area	Bsrat et al. (2018)	4.3	1.8–10.3						10.7	2.4	3	0.49	0.0%
Ayehu et al. (2018)		2.1	0.7–6.4	6.4										
Alebie et al. (2019)		2.1	1.2–3.5	29										
Yohannes et al. (2019)		2.1	1.43.1	53.9										
Pooled RR		2.2	1.7–3	100										
Domestic animals near sleeping areas	Ayehu et al. (2018)	2.8	1–7.6	27	3.9	2	0.14	48.8%	0.18					
	Alebie et al. (2019)	5.3	1.7–16.5	23.4										
	Yohannes et al. (2019)	1.6	0.9–2.7	49.6										
	Pooled RR	2.5	1.3–4.9	100										
Travel history	Abera et al. (2016)	1.8	0.7–4.5	58	0.4	1	0.52	0.0%	0.00					
	Ayehu et al. (2018)	2.9	1–8.3	42										
	Pooled RR	2.2	1.1–4.4	100										

Table 4 continued

Variables	Authors	RR	95% CI	% Weight	Heterogeneity chi-squared	df	p value	I-squared	Tau-squared
Presence of acacia near the sleeping area	Bsrat et al. (2018)	1.8	0.8–3.9	49.4	7.2	1	0.01	86.1	0.91
	Alebie et al. (2019)	7.6	3.7–15.7	50.6					
	Pooled RR	3.7	0.9–15.5	100					
Presence of black soil	Bsrat et al. (2018)	1.7	0.7–3.9	58.4	0.6	1	0.43	0.0%	0.00
	Aychu et al. (2018)	2.9	1.1–7.7	41.7					
	Pooled RR	2.1	1.1–4	100					
Occupation	Abera et al (2016)	1.1	0.3–3.6	10.9	0.1	2	0.95	0.0%	0.00
	Bsrat et al. (2018)	1.2	0.7–2.5	27.7					
	Alebie et al. (2019)	1.0	0.6–1.7	61.5					
	Pooled RR	1.1	0.7–1.6	100					
Presence of gorge	Bsrat et al. (2015)	1.4	1.1–1.7	51.7	15.9	1	0.00	93.7	0.44
	Yohannes et al. (2019)	3.6	2.4–5.4	48.4					
	Pooled RR	2.2	0.9–5.6	100					




Fig. 4 Funnel plot showing a risk of bias on leishmaniasis prevalence and standard error in Ethiopia

sleeping outdoors [34, 36, 38], age [36], presence of a gorge within a 300-m radius of the sleeping area [24, 30], presence of acacia [33, 36], and travel history to leishmaniasis endemic areas [27] were significantly associated with human leishmaniasis.

CONCLUSION

The prevalence of leishmaniasis remains high in Ethiopia (9.13%), and gender (male) and the

presence of hyraxes within a 300-m radius of the sleeping area were significant risk factors. Even though there is a reduction in the magnitude of leishmaniasis and there are advances in diagnosis and treatments [16, 17], this disease remains challenging to assess and manage in developing countries like Ethiopia. Substantial gaps and inconsistencies were seen between the findings of the individual articles and systematic review and meta-analysis, clearly indicating the need for more intensive and national

studies on this condition. Leishmaniasis was one of the WHO's targets for elimination and control by 2020. However, our findings highlight that leishmaniasis is still a prevalent and neglected disease, contributing its share to the global burden of neglected tropical diseases (NTD). Since the current medications are decades old and full of limitations [35], new vaccines, methods of diagnosis, and treatment for its eradication should be given priority, and prophylaxes should also be considered to prevent relapse. Researchers around the world might also consider their investment in human leishmaniasis, especially in innovation for new treatments and diagnostics that can be affordable for developing countries. Epidemiological investigations of possible risk factors for human leishmaniasis, clinical trials for evidence-based practices, investigations of treatment failure, and investigation on the geographical distribution of hyraxes are recommended. Mass screening and follow-ups of interventions are also recommended.

ACKNOWLEDGEMENTS

The authors thank Adigrat University and Berhane Fisha for coordinating and supporting the development and preparation of the manuscript.

Funding. No funding or sponsorship was received for this study or publication of this article.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Authorship Contributions. MH idea conception, proposal preparation, data analysis, wrote the paper, presented the paper, and drafted the manuscript. PP, KG, JN, EA, TH, YA, GG, HH, DG, and AG cooperated in the development of the proposal, presentation of the

proposal, and data analysis and critically reviewed the manuscript. All authors accepted the final manuscript and took part in the evaluation and review of the manuscript.

Disclosures. Mekonnen Haftom, Pammla Petrucka, Kbrom Gemechu, Jemila Nesro, Embay Amare, Tsegu Hailu, Yohannes Ashebir, Gdiom Gebreheat, Haftea Hagos, Destaalem Gebremedhin and Alem Gebremariam declare that they have no competing interests.

Compliance with Ethics Guideline. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Data Availability. The datasets used and analyzed during this study are available from the corresponding author on reasonable request.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

REFERENCES

1. Alvar J, Vélez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. *PLoS One*. 2012;7(5):e35671.

2. Bailey F, Mondragon-Shem K, Hotez P, et al. A new perspective on cutaneous leishmaniasis—implications for global prevalence and burden of disease estimates. *PLoS Negl Trop Dis*. 2017;11(8):e0005739.
3. Deribe K, Meribo K, Gebre T, et al. The burden of neglected tropical diseases in Ethiopia, and opportunities for integrated control and elimination. *Parasit Vectors*. 2012;5(1):240.
4. Palatnik-de-Sousa CB, Day MJ. One Health: the global challenge of epidemic and endemic leishmaniasis. *Parasit Vectors*. 2011;4(1):1–10.
5. Esch KJ, Petersen CA. Transmission and epidemiology of zoonotic protozoal diseases of companion animals. *Clin Microbiol Rev*. 2013;26(1):58–85.
6. Assefa A. Leishmaniasis in Ethiopia: a systematic review and meta-analysis of prevalence in animals and humans. *Heliyon*. 2018;4(8):e00723.
7. Deribew A, Kebede B, Tessema GA, et al. Mortality and disability-adjusted life-years (dalys) for common neglected tropical diseases in Ethiopia, 1990–2015: evidence from the global burden of disease study 2015. *Ethiop Med J*. 2017;55(1):3.
8. Chappuis F, Sundar S, Hailu A, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? *Nat Rev Microbiol*. 2007;5(11):873–82.
9. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. *Lancet*. 2005;366(9496):1561–77.
10. Kühne V, Rezaei Z, Pitzinger P, Büscher P. Systematic review on antigens for serodiagnosis of visceral leishmaniasis, with a focus on East Africa. *PLoS Negl Trop Dis*. 2019;13(8):e0007658.
11. Den Boer M, Argaw D, Jannin J, Alvar J. Leishmaniasis impact and treatment access. *Clin Microbiol Infect*. 2011;17(10):1471–7.
12. Hotez PJ, Molyneux DH, Fenwick A, et al. Control of neglected tropical diseases. *N Engl J Med*. 2007;357(10):1018–27.
13. Tsegaw T, Gadisa E, Seid A, et al. Identification of environmental parameters and risk mapping of visceral leishmaniasis in Ethiopia by using geographical information systems and a statistical approach. *Geospatial Health*. 2013;7(2):299–308.
14. Hailu A, Gramiccia M, Kager P. Visceral leishmaniasis in Aba-Roba, south-western Ethiopia: prevalence and incidence of active and subclinical infections. *Ann Trop Med Parasitol*. 2009;103(8):659–70.
15. Khalil E, Zijlstra EE, Kager PA, El Hassan AM. Epidemiology and clinical manifestations of *Leishmania donovani* infection in two villages in an endemic area in eastern Sudan. *Trop Med Int Health*. 2002;7(1):35–44.
16. Renslo AR, McKerrow JH. Drug discovery and development for neglected parasitic diseases. *Nat Chem Biol*. 2006;2(12):701.
17. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug development for neglected diseases: a deficient market and a public-health policy failure. *Lancet*. 2002;359(9324):2188–94.
18. Gadisa E, Tsegaw T, Abera A, et al. Eco-epidemiology of visceral leishmaniasis in Ethiopia. *Parasit Vectors*. 2015;8(1):381.
19. Pires M, Wright B, Kaye PM, et al. The impact of leishmaniasis on mental health and psychosocial well-being: a systematic review. *PLoS One*. 2019;14(10):e0223313.
20. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med*. 2009;151(4):264–9.
21. Modesti PA, Reboldi G, Cappuccio FP, et al. Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. *PLoS One*. 2016;11(1):e0147601.
22. Ali A, Ashford R. Visceral leishmaniasis in Ethiopia. I. Cross-sectional leishmanin skin test in an endemic locality. *Ann Trop Med Parasitol*. 1993;87(2):157–61.
23. Wondimeneh Y, Takele Y, Atnafu A, Ferede G, Muluye D. Trend analysis of visceral leishmaniasis at Addis Zemen health center, Northwest Ethiopia. *BioMed Res Int*. 2014;2014:545393. <https://doi.org/10.1155/2014/545393>.
24. Yohannes M, Abebe Z, Boelee E. Prevalence and environmental determinants of cutaneous leishmaniasis in rural communities in Tigray, northern Ethiopia. *PLoS Negl Trop Dis*. 2019;13(9):e0007722.
25. Abera A, Tasew G, Tsegaw T, et al. Visceral leishmaniasis in Benishangul-Gumuz regional state, Western Ethiopia: reemerging or emerging? *Am J Trop Med Hygiene*. 2016;95(1):104–8.
26. Alebie G, Worku A, Yohannes S, Urga B, Hailu A, Tadesse D. Epidemiology of visceral leishmaniasis in Shebelle Zone of Somali Region, eastern Ethiopia. *Parasit Vectors*. 2019;12(1):209.
27. Ayehu A, Aschale Y, Lemma W, et al. Seroprevalence of asymptomatic leishmania donovani

- among laborers and associated risk factors in agricultural camps of West Armachiho District, North-west Ethiopia: a cross-sectional study. *J Parasitol Res.* 2018;2018:5751743. <https://doi.org/10.1155/2018/5751743>
28. Bekele F, Belay T, Zeynudin A, Hailu A. Visceral leishmaniasis in selected communities of Hamar and Banna-Tsamai districts in Lower Omo Valley, South West Ethiopia: Sero-epidemiological and Leishmanin Skin Test Surveys. *PLoS One.* 2018;13(5):e0197430. <https://doi.org/10.1371/journal.pone.0197430>
29. Bsrat A, Berhe M, Gadissa E, et al. Serological investigation of visceral Leishmania infection in human and its associated risk factors in Welkait District, Western Tigray, Ethiopia. *Parasite Epidemiol Control.* 2018;3(1):13–20.
30. Bsrat A, Berhe N, Balkew M, et al. Epidemiological study of cutaneous leishmaniasis in Saesie Tsaedemba district, eastern Tigray, northern Ethiopia. *Parasit Vectors.* 2015;8(1):149.
31. Negera E, Gadisa E, Yamuah L, et al. Outbreak of cutaneous leishmaniasis in Silti woreda, Ethiopia: risk factor assessment and causative agent identification. *Trans R Soc Trop Med Hyg.* 2008;102(9):883–90.
32. Gebremichael TD, Bariagabr FH, Abreha HH. Incidence and trends of leishmaniasis and its risk factors in Humera, Western Tigray. *J Parasitol Res.* 2018;2018:8463097.
33. Argaw D, Mulugeta A, Herrero M, et al. Risk factors for visceral leishmaniasis among residents and migrants in Kafta-Humera, Ethiopia. *PLoS Negl Trop Dis.* 2013;7(11):e2543.
34. Hotez PJ, Kamath A. Neglected tropical diseases in sub-Saharan Africa: review of their prevalence, distribution, and disease burden. *PLoS Negl Trop Dis.* 2009;3(8):e412.
35. van Griensven J, Gadisa E, Aseffa A, Hailu A, Beshah AB, Diro E. Treatment of cutaneous leishmaniasis caused by *Leishmania aethiopica*: a systematic review. *PLoS Negl Trop Dis.* 2016;10(3):e0004495.
36. Nackers F, Mueller YK, Salih N, et al. Determinants of visceral leishmaniasis: a case-control study in Gedaref State, Sudan. *PLoS Negl Trop Dis.* 2015;9(11):e0004187.
37. van Henten S, Adriaansen W, Fikre H, et al. Cutaneous leishmaniasis due to *leishmania aethiopica*. *EClinicalMedicine.* 2018;6:69–81.
38. Yared S, Deribe K, Gebreselassie A, et al. Risk factors of visceral leishmaniasis: a case control study in north-western Ethiopia. *Parasit Vectors.* 2014;7(1):470.